Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Samuel M Moskowitz, M.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01AI067653 (MOSKOWITZ, SAMUEL M) May 15, 2007 - Apr 30, 2012
    Polymyxin-resistant Pseudomonas in CF Lung Infection
    Role: Principal Investigator
  2. R21HL079093 (MOSKOWITZ, SAMUEL M) Dec 10, 2004 - Nov 30, 2006
    Influence of ENaC Regulators on CF Lung Severity
    Role: Principal Investigator
  3. K08HL067903 (MOSKOWITZ, SAMUEL M) Aug 5, 2001 - Jul 31, 2006
    Host-Pathogen Interactions in Cystic Fibrosis
    Role: Principal Investigator
  4. M01RR000037 (RAMSEY, PAUL G.) Jan 1, 1974 - Mar 31, 2009
    General Clinical Research Center
    Role: Co-Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, Bruinsma BG, Harris C, Lam AP, Lou Y, Moskowitz SM, Tian S, Yuan J, Waltz D, Mall MA. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Lancet Respir Med. 2022 03; 10(3):267-277. PMID: 34942085.
    Citations: 2     Fields:    Translation:CTClinical Trials
  2. Barry PJ, Mall MA, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D. Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. N Engl J Med. 2021 08 26; 385(9):815-825. PMID: 34437784.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  3. Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, McNally P, Ramsey BW, Rayment JH, Rowe SM, Tullis E, Ahluwalia N, Chu C, Ho T, Moskowitz SM, Noel S, Tian S, Waltz D, Weinstock TG, Xuan F, Wainwright CE, McColley SA. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med. 2021 06 15; 203(12):1522-1532. PMID: 33734030.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  4. Griese M, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, Quon BS, Ringshausen FC, Taylor-Cousar JL, Withers NJ, Moskowitz SM, Daines CL. Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. Am J Respir Crit Care Med. 2021 02 01; 203(3):381-385. PMID: 32969708.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  5. Tsai A, Wu SP, Haseltine E, Kumar S, Moskowitz SM, Panorchan P, Shah K. Correction to: Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor. Pulm Ther. 2020 Dec; 6(2):287. PMID: 32856286.
  6. Tsai A, Wu SP, Haseltine E, Kumar S, Moskowitz SM, Panorchan P, Shah K. Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor. Pulm Ther. 2020 Dec; 6(2):275-286. PMID: 32734574.
  7. Cuthbertson L, Walker AW, Oliver AE, Rogers GB, Rivett DW, Hampton TH, Ashare A, Elborn JS, De Soyza A, Carroll MP, Hoffman LR, Lanyon C, Moskowitz SM, O'Toole GA, Parkhill J, Planet PJ, Teneback CC, Tunney MM, Zuckerman JB, Bruce KD, van der Gast CJ. Lung function and microbiota diversity in cystic fibrosis. Microbiome. 2020 04 02; 8(1):45. PMID: 32238195.
    Citations: 25     Fields:    Translation:HumansCells
  8. Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019 11 23; 394(10212):1940-1948. PMID: 31679946.
    Citations: 174     Fields:    Translation:HumansCTClinical Trials
  9. Middleton PG, Mall MA, Drevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019 11 07; 381(19):1809-1819. PMID: 31697873.
    Citations: 252     Fields:    Translation:HumansCTClinical Trials
  10. Taylor-Cousar JL, Mall MA, Ramsey BW, McKone EF, Tullis E, Marigowda G, McKee CM, Waltz D, Moskowitz SM, Savage J, Xuan F, Rowe SM. Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. ERJ Open Res. 2019 Apr; 5(2). PMID: 31218221.
    Citations: 22     
  11. Friedman D, Linnemann RW, Altstein LL, Georgiopoulos AM, Islam S, Bach KT, St John A, Fracchia MS, Neuringer I, Lapey A, Sicilian L, Moskowitz SM, Yonker LM. Effects of a primary palliative care intervention on quality of life and mental health in cystic fibrosis. Pediatr Pulmonol. 2019 07; 54(7):984-992. PMID: 30854795.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  12. Han ML, Zhu Y, Creek DJ, Lin YW, Gutu AD, Hertzog P, Purcell T, Shen HH, Moskowitz SM, Velkov T, Li J. Comparative Metabolomics and Transcriptomics Reveal Multiple Pathways Associated with Polymyxin Killing in Pseudomonas aeruginosa. mSystems. 2019 Jan-Feb; 4(1). PMID: 30637340.
    Citations: 21     
  13. Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 10 25; 379(17):1599-1611. PMID: 30334693.
    Citations: 103     Fields:    Translation:HumansCellsCTClinical Trials
  14. Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 10 25; 379(17):1612-1620. PMID: 30334692.
    Citations: 180     Fields:    Translation:HumansCTClinical Trials
  15. Linnemann RW, Friedman D, Altstein LL, Islam S, Bach KT, Georgiopoulos AM, Moskowitz SM, Yonker LM. Advance Care Planning Experiences and Preferences among People with Cystic Fibrosis. J Palliat Med. 2019 02; 22(2):138-144. PMID: 30335569.
    Citations: 4     Fields:    Translation:Humans
  16. Han ML, Zhu Y, Creek DJ, Lin YW, Anderson D, Shen HH, Tsuji B, Gutu AD, Moskowitz SM, Velkov T, Li J. Alterations of Metabolic and Lipid Profiles in Polymyxin-Resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2018 06; 62(6). PMID: 29632014.
    Citations: 25     Fields:    Translation:Cells
  17. Han ML, Velkov T, Zhu Y, Roberts KD, Le Brun AP, Chow SH, Gutu AD, Moskowitz SM, Shen HH, Li J. Polymyxin-Induced Lipid A Deacylation in Pseudomonas aeruginosa Perturbs Polymyxin Penetration and Confers High-Level Resistance. ACS Chem Biol. 2018 01 19; 13(1):121-130. PMID: 29182311.
    Citations: 24     Fields:    Translation:Cells
  18. Koeva M, Gutu AD, Hebert W, Wager JD, Yonker LM, O'Toole GA, Ausubel FM, Moskowitz SM, Joseph-McCarthy D. An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections. Antimicrob Agents Chemother. 2017 12; 61(12). PMID: 28923873.
    Citations: 16     Fields:    Translation:HumansCells
  19. Han ML, Shen HH, Hansford KA, Schneider EK, Sivanesan S, Roberts KD, Thompson PE, Le Brun AP, Zhu Y, Sani MA, Separovic F, Blaskovich MAT, Baker MA, Moskowitz SM, Cooper MA, Li J, Velkov T. Investigating the Interaction of Octapeptin A3 with Model Bacterial Membranes. ACS Infect Dis. 2017 08 11; 3(8):606-619. PMID: 28695731.
    Citations: 8     Fields:    Translation:Cells
  20. Friedman D, Linnemann RW, Altstein LL, Islam S, Bach KT, Lamb C, Volpe J, Doolittle C, St John A, O'Malley PJ, Sawicki GS, Georgiopoulos AM, Yonker LM, Moskowitz SM. The CF-CARES primary palliative care model: A CF-specific structured assessment of symptoms, distress, and coping. J Cyst Fibros. 2018 01; 17(1):71-77. PMID: 28302366.
    Citations: 6     Fields:    Translation:Humans
  21. Meylan S, Porter CBM, Yang JH, Belenky P, Gutierrez A, Lobritz MA, Park J, Kim SH, Moskowitz SM, Collins JJ. Carbon Sources Tune Antibiotic Susceptibility in Pseudomonas aeruginosa via Tricarboxylic Acid Cycle Control. Cell Chem Biol. 2017 Feb 16; 24(2):195-206. PMID: 28111098.
    Citations: 107     Fields:    Translation:Cells
  22. Brackett CM, Furlani RE, Anderson RG, Krishnamurthy A, Melander RJ, Moskowitz SM, Ernst RK, Melander C. Second Generation Modifiers of Colistin Resistance Show Enhanced Activity and Lower Inherent Toxicity. Tetrahedron. 2016 Jun 23; 72(25):3549-3553. PMID: 27429479.
    Citations: 12     Fields:    
  23. Ong W, Nowak P, Cu Y, Schopf L, Bourassa J, Enlow E, Moskowitz SM, Chen H. Sustained Pulmonary Delivery of a Water-Soluble Antibiotic Without Encapsulating Carriers. Pharm Res. 2016 Mar; 33(3):563-72. PMID: 26508478.
    Citations: 1     Fields:    Translation:HumansAnimals
  24. Beringer PM, Bensman TJ, Ho H, Agnello M, Denovel N, Nguyen A, Wong-Beringer A, She R, Tran DQ, Moskowitz SM, Selsted ME. Rhesus ?-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa. J Antimicrob Chemother. 2016 Jan; 71(1):181-8. PMID: 26433781.
    Citations: 13     Fields:    Translation:HumansAnimalsCells
  25. Moskowitz SM, Shailam R, Mark EJ. CASE RECORDS of the MASSACHUSETTS GENERAL HOSPITAL. Case 25-2015. An 8-Year-Old Girl with a Chest-Wall Mass and a Pleural Effusion. N Engl J Med. 2015 Aug 13; 373(7):657-67. PMID: 26267626.
    Citations: 8     Fields:    Translation:HumansCells
  26. Hittle LE, Powell DA, Jones JW, Tofigh M, Goodlett DR, Moskowitz SM, Ernst RK. Site-specific activity of the acyltransferases HtrB1 and HtrB2 in Pseudomonas aeruginosa lipid A biosynthesis. Pathog Dis. 2015 Nov; 73(8):ftv053. PMID: 26223882.
    Citations: 13     Fields:    Translation:HumansCells
  27. Gutu AD, Rodgers NS, Park J, Moskowitz SM. Pseudomonas aeruginosa high-level resistance to polymyxins and other antimicrobial peptides requires cprA, a gene that is disrupted in the PAO1 strain. Antimicrob Agents Chemother. 2015 Sep; 59(9):5377-87. PMID: 26100714.
    Citations: 11     Fields:    Translation:Cells
  28. Linnemann RW, O'Malley PJ, Friedman D, Georgiopoulos AM, Buxton D, Altstein LL, Sicilian L, Lapey A, Sawicki GS, Moskowitz SM. Development and evaluation of a palliative care curriculum for cystic fibrosis healthcare providers. J Cyst Fibros. 2016 Jan; 15(1):90-5. PMID: 25817162.
    Citations: 9     Fields:    Translation:Humans
  29. Zemke AC, Shiva S, Burns JL, Moskowitz SM, Pilewski JM, Gladwin MT, Bomberger JM. Nitrite modulates bacterial antibiotic susceptibility and biofilm formation in association with airway epithelial cells. Free Radic Biol Med. 2014 Dec; 77:307-16. PMID: 25229185.
    Citations: 28     Fields:    Translation:HumansCells
  30. Caceres SM, Malcolm KC, Taylor-Cousar JL, Nichols DP, Saavedra MT, Bratton DL, Moskowitz SM, Burns JL, Nick JA. Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products. Antimicrob Agents Chemother. 2014 Nov; 58(11):6851-60. PMID: 25182651.
    Citations: 23     Fields:    Translation:HumansCells
  31. Wurst JM, Drake EJ, Theriault JR, Jewett IT, VerPlank L, Perez JR, Dandapani S, Palmer M, Moskowitz SM, Schreiber SL, Munoz B, Gulick AM. Identification of inhibitors of PvdQ, an enzyme involved in the synthesis of the siderophore pyoverdine. ACS Chem Biol. 2014 Jul 18; 9(7):1536-44. PMID: 24824984.
    Citations: 11     Fields:    Translation:HumansCells
  32. Yoo DG, Winn M, Pang L, Moskowitz SM, Malech HL, Leto TL, Rada B. Release of cystic fibrosis airway inflammatory markers from Pseudomonas aeruginosa-stimulated human neutrophils involves NADPH oxidase-dependent extracellular DNA trap formation. J Immunol. 2014 May 15; 192(10):4728-38. PMID: 24740504.
    Citations: 44     Fields:    Translation:HumansCellsCTClinical Trials
  33. Yoo DG, Floyd M, Winn M, Moskowitz SM, Rada B. NET formation induced by Pseudomonas aeruginosa cystic fibrosis isolates measured as release of myeloperoxidase-DNA and neutrophil elastase-DNA complexes. Immunol Lett. 2014 Aug; 160(2):186-94. PMID: 24670966.
    Citations: 56     Fields:    Translation:HumansCells
  34. Nick JA, Moskowitz SM, Chmiel JF, Forssén AV, Kim SH, Saavedra MT, Saiman L, Taylor-Cousar JL, Nichols DP. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc. 2014 Mar; 11(3):342-50. PMID: 24476418.
    Citations: 25     Fields:    Translation:HumansCells
  35. Thaipisuttikul I, Hittle LE, Chandra R, Zangari D, Dixon CL, Garrett TA, Rasko DA, Dasgupta N, Moskowitz SM, Malmström L, Goodlett DR, Miller SI, Bishop RE, Ernst RK. A divergent Pseudomonas aeruginosa palmitoyltransferase essential for cystic fibrosis-specific lipid A. Mol Microbiol. 2014 Jan; 91(1):158-74. PMID: 24283944.
    Citations: 18     Fields:    Translation:HumansCells
  36. Gutu AD, Sgambati N, Strasbourger P, Brannon MK, Jacobs MA, Haugen E, Kaul RK, Johansen HK, Høiby N, Moskowitz SM. Polymyxin resistance of Pseudomonas aeruginosa phoQ mutants is dependent on additional two-component regulatory systems. Antimicrob Agents Chemother. 2013 May; 57(5):2204-15. PMID: 23459479.
    Citations: 46     Fields:    Translation:HumansCells
  37. Nichols DP, Caceres S, Caverly L, Fratelli C, Kim SH, Malcolm K, Poch KR, Saavedra M, Solomon G, Taylor-Cousar J, Moskowitz S, Nick JA. Effects of azithromycin in Pseudomonas aeruginosa burn wound infection. J Surg Res. 2013 Aug; 183(2):767-76. PMID: 23478086.
    Citations: 15     Fields:    Translation:AnimalsCells
  38. Rada B, Jendrysik MA, Pang L, Hayes CP, Yoo DG, Park JJ, Moskowitz SM, Malech HL, Leto TL. Pyocyanin-enhanced neutrophil extracellular trap formation requires the NADPH oxidase. PLoS One. 2013; 8(1):e54205. PMID: 23342104.
    Citations: 44     Fields:    Translation:HumansCells
  39. Moskowitz SM, Brannon MK, Dasgupta N, Pier M, Sgambati N, Miller AK, Selgrade SE, Miller SI, Denton M, Conway SP, Johansen HK, Høiby N. PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients. Antimicrob Agents Chemother. 2012 Feb; 56(2):1019-30. PMID: 22106224.
    Citations: 76     Fields:    Translation:HumansCells
  40. Miller AK, Brannon MK, Stevens L, Johansen HK, Selgrade SE, Miller SI, Høiby N, Moskowitz SM. PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients. Antimicrob Agents Chemother. 2011 Dec; 55(12):5761-9. PMID: 21968359.
    Citations: 86     Fields:    Translation:HumansCells
  41. Young RL, Malcolm KC, Kret JE, Caceres SM, Poch KR, Nichols DP, Taylor-Cousar JL, Saavedra MT, Randell SH, Vasil ML, Burns JL, Moskowitz SM, Nick JA. Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR. PLoS One. 2011; 6(9):e23637. PMID: 21909403.
    Citations: 99     Fields:    Translation:HumansCells
  42. Moskowitz SM, Emerson JC, McNamara S, Shell RD, Orenstein DM, Rosenbluth D, Katz MF, Ahrens R, Hornick D, Joseph PM, Gibson RL, Aitken ML, Benton WW, Burns JL. Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatr Pulmonol. 2011 Feb; 46(2):184-92. PMID: 20963843.
    Citations: 20     Fields:    Translation:HumansCells
  43. Moskowitz SM, Garber E, Chen Y, Clock SA, Tabibi S, Miller AK, Doctor M, Saiman L. Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia. J Antimicrob Chemother. 2010 Jul; 65(7):1416-23. PMID: 20430789.
    Citations: 21     Fields:    Translation:HumansCells
  44. Moskowitz SM, Wiener-Kronish JP. Mechanisms of bacterial virulence in pulmonary infections. Curr Opin Crit Care. 2010 Feb; 16(1):8-12. PMID: 19956071.
    Citations: 4     Fields:    Translation:HumansCells
  45. Moskowitz SM, Ernst RK. The role of Pseudomonas lipopolysaccharide in cystic fibrosis airway infection. Subcell Biochem. 2010; 53:241-53. PMID: 20593270.
    Citations: 36     Fields:    Translation:HumansCells
  46. Brannon MK, Davis JM, Mathias JR, Hall CJ, Emerson JC, Crosier PS, Huttenlocher A, Ramakrishnan L, Moskowitz SM. Pseudomonas aeruginosa Type III secretion system interacts with phagocytes to modulate systemic infection of zebrafish embryos. Cell Microbiol. 2009 May; 11(5):755-68. PMID: 19207728.
    Citations: 72     Fields:    Translation:AnimalsCells
  47. Moskowitz SM, Chmiel JF, Sternen DL, Cheng E, Gibson RL, Marshall SG, Cutting GR. Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genet Med. 2008 Dec; 10(12):851-68. PMID: 19092437.
    Citations: 47     Fields:    Translation:Humans
  48. Mena A, Smith EE, Burns JL, Speert DP, Moskowitz SM, Perez JL, Oliver A. Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J Bacteriol. 2008 Dec; 190(24):7910-7. PMID: 18849421.
    Citations: 99     Fields:    Translation:HumansCells
  49. Moskowitz SM, Silva SJ, Mayer-Hamblett N, Pasta DJ, Mink DR, Mabie JA, Konstan MW, Wagener JS. Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr Pulmonol. 2008 Sep; 43(9):874-81. PMID: 18668689.
    Citations: 24     Fields:    Translation:Humans
  50. Johansen HK, Moskowitz SM, Ciofu O, Pressler T, Høiby N. Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cyst Fibros. 2008 Sep; 7(5):391-7. PMID: 18358794.
    Citations: 51     Fields:    Translation:HumansCellsPHPublic Health
  51. Ernst RK, Moskowitz SM, Emerson JC, Kraig GM, Adams KN, Harvey MD, Ramsey B, Speert DP, Burns JL, Miller SI. Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis. J Infect Dis. 2007 Oct 01; 196(7):1088-92. PMID: 17763333.
    Citations: 47     Fields:    Translation:HumansCells
  52. Smith EE, Buckley DG, Wu Z, Saenphimmachak C, Hoffman LR, D'Argenio DA, Miller SI, Ramsey BW, Speert DP, Moskowitz SM, Burns JL, Kaul R, Olson MV. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci U S A. 2006 May 30; 103(22):8487-92. PMID: 16687478.
    Citations: 606     Fields:    Translation:HumansCells
  53. Ernst RK, Adams KN, Moskowitz SM, Kraig GM, Kawasaki K, Stead CM, Trent MS, Miller SI. The Pseudomonas aeruginosa lipid A deacylase: selection for expression and loss within the cystic fibrosis airway. J Bacteriol. 2006 Jan; 188(1):191-201. PMID: 16352835.
    Citations: 60     Fields:    Translation:HumansCells
  54. Moskowitz SM, Foster JM, Emerson JC, Gibson RL, Burns JL. Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. J Antimicrob Chemother. 2005 Nov; 56(5):879-86. PMID: 16188918.
    Citations: 18     Fields:    Translation:HumansCells
  55. Moskowitz SM, Gibson RL, Effmann EL. Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment. Pediatr Radiol. 2005 Aug; 35(8):739-57. PMID: 15868140.
    Citations: 10     Fields:    Translation:Humans
  56. Johnson LN, Han JY, Moskowitz SM, Burns JL, Qin X, Englund JA. Pandoraea bacteremia in a cystic fibrosis patient with associated systemic illness. Pediatr Infect Dis J. 2004 Sep; 23(9):881-2. PMID: 15361734.
    Citations: 15     Fields:    Translation:HumansCells
  57. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol. 2004 May; 42(5):1915-22. PMID: 15131149.
    Citations: 126     Fields:    Translation:HumansCells
  58. Moskowitz SM, Ernst RK, Miller SI. PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J Bacteriol. 2004 Jan; 186(2):575-9. PMID: 14702327.
    Citations: 154     Fields:    Translation:Cells
  59. Ernst RK, Hajjar AM, Tsai JH, Moskowitz SM, Wilson CB, Miller SI. Pseudomonas aeruginosa lipid A diversity and its recognition by Toll-like receptor 4. J Endotoxin Res. 2003; 9(6):395-400. PMID: 14733728.
    Citations: 42     Fields:    Translation:HumansCells
  60. Bach G, Moskowitz SM, Tieu PT, Matynia A, Neufeld EF. Molecular analysis of Hurler syndrome in Druze and Muslim Arab patients in Israel: multiple allelic mutations of the IDUA gene in a small geographic area. Am J Hum Genet. 1993 Aug; 53(2):330-8. PMID: 8328452.
    Citations: 25     Fields:    Translation:HumansCellsPHPublic Health
  61. Moskowitz SM, Tieu PT, Neufeld EF. A deletion/insertion mutation in the IDUA gene in a Libyan Jewish patient with Hurler syndrome (mucopolysaccharidosis IH). Hum Mutat. 1993; 2(1):71-3. PMID: 8477267.
    Citations: 7     Fields:    Translation:HumansCells
  62. Moskowitz SM, Tieu PT, Neufeld EF. Mutation in Scheie syndrome (MPS IS): a G-->A transition creates new splice site in intron 5 of one IDUA allele. Hum Mutat. 1993; 2(2):141-4. PMID: 8318992.
    Citations: 3     Fields:    Translation:HumansCells
  63. Stoltzfus LJ, Sosa-Pineda B, Moskowitz SM, Menon KP, Dlott B, Hooper L, Teplow DB, Shull RM, Neufeld EF. Cloning and characterization of cDNA encoding canine alpha-L-iduronidase. mRNA deficiency in mucopolysaccharidosis I dog. J Biol Chem. 1992 Apr 05; 267(10):6570-5. PMID: 1551868.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  64. Paw BH, Moskowitz SM, Uhrhammer N, Wright N, Kaback MM, Neufeld EF. Juvenile GM2 gangliosidosis caused by substitution of histidine for arginine at position 499 or 504 of the alpha-subunit of beta-hexosaminidase. J Biol Chem. 1990 Jun 05; 265(16):9452-7. PMID: 2140574.
    Citations: 22     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Moskowitz's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (308)
Co-Authors (15)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.